<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645550</url>
  </required_header>
  <id_info>
    <org_study_id>YZUC-005</org_study_id>
    <nct_id>NCT04645550</nct_id>
  </id_info>
  <brief_title>Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）</brief_title>
  <official_title>Efficacy and Safety of Apixaban, Warfarin and Aspirin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yangzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Apixaban, Warfarin and Aspirin&#xD;
      Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver&#xD;
      Cirrhotic Patients after Laparoscopic Splenectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After successful screening the cases of cirrhosis of liver irrespective of the etiology who&#xD;
      have non tumor portal vein thrombosis will be enrolled. The baseline Doppler parameter will&#xD;
      be recorded and the patient will be randomized into apixaban, warfarin or aspirin group. From&#xD;
      postoperative day three, patients in apixaban group will receive oral Apixaban 2.5mg bid for&#xD;
      six months, patients in warfarin group will receive oral Warfarin 2.5mg qd with titration of&#xD;
      dose to maintain a target INR of 2-3 for six months, patients in aspirin group will receive&#xD;
      oral Aspirin Enterie Ccoated Tablets 100mg qd for six months. All groups will be along with&#xD;
      five days of subcutaneous injection of Low Molecular Weight Heparin and three months of oral&#xD;
      Dipyridamole. Every three months the Doppler screening for the occurrence of portal vein&#xD;
      thrombus (PVT) or spleno-mesenteric thrombosis will be done for all patients. All groups will&#xD;
      receive the therapy for six months irrespective of the Doppler findings in relation to portal&#xD;
      vein thrombus occurrence. Then six months monitoring will be done in the three groups as per&#xD;
      the primary or secondary outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 22, 2020</start_date>
  <completion_date type="Anticipated">November 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of patients who will suffer PVT or spleno-mesenteric thrombosis among oral anticoagulant Apixaban with dipyridamole group, oral Warfarin with dipyridamole group and oral Aspirin with dipyridamole group during the study period</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients who will show improvement in Child Pugh (&gt;2 points) in three groups</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients who will show improvement in Model for End Stage Liver Disease (MELD)(&gt;4 points) in three groups</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients who will show decrease in hepatic decompensation defined as development of ascites, PSE, portal hypertensive bleeding, jaundice, spontaneous bacterial peritonitis, or systemic infection</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients who will suffer from hepatocellular carcinoma in three groups.</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in three groups.</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Splenectomy; Status</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Hypertension, Portal</condition>
  <arm_group>
    <arm_group_label>Apixaban with dipyridamole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Apixaban 2.5mg bid for six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin with dipyridamole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for six months irrespective of the occurrence of portal vein thrombus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin with dipyridamole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.</description>
    <arm_group_label>Apixaban with dipyridamole</arm_group_label>
    <other_name>ELIQUIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.</description>
    <arm_group_label>Warfarin with dipyridamole</arm_group_label>
    <other_name>Warfarin Sodium</other_name>
    <other_name>Athrombine</other_name>
    <other_name>COUMADIN</other_name>
    <other_name>PANAWARFIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.</description>
    <arm_group_label>Aspirin with dipyridamole</arm_group_label>
    <other_name>Acenterine</other_name>
    <other_name>Acetard</other_name>
    <other_name>Acetophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyridamole</intervention_name>
    <description>From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.</description>
    <arm_group_label>Apixaban with dipyridamole</arm_group_label>
    <arm_group_label>Aspirin with dipyridamole</arm_group_label>
    <arm_group_label>Warfarin with dipyridamole</arm_group_label>
    <other_name>Gardoxin</other_name>
    <other_name>Coribon</other_name>
    <other_name>Curantyl</other_name>
    <other_name>Dilaplus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low molecular weight heparin</intervention_name>
    <description>From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.</description>
    <arm_group_label>Apixaban with dipyridamole</arm_group_label>
    <arm_group_label>Aspirin with dipyridamole</arm_group_label>
    <arm_group_label>Warfarin with dipyridamole</arm_group_label>
    <other_name>Fraxiparine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A clinical, radiological or histologic diagnosis of cirrhosis of any etiology&#xD;
&#xD;
          -  Splenomegaly with secondary hypersplenism&#xD;
&#xD;
          -  No evidence of PVT or spleno-mesenteric thrombosis by ultrasound evaluation and&#xD;
             angio-CT&#xD;
&#xD;
          -  Informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatocellular carcinoma or any other malignancy&#xD;
&#xD;
          -  Hypercoagulable state other than the liver disease related&#xD;
&#xD;
          -  DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs&#xD;
&#xD;
          -  Base line INR &gt;2&#xD;
&#xD;
          -  Child-Pugh grade C&#xD;
&#xD;
          -  Recent peptic ulcer disease&#xD;
&#xD;
          -  History of Hemorrhagic stroke&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Uncontrolled Hypertension&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dou-Sheng Bai Bai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Medical College of Yangzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guo-Qing Jiang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Medical College of Yangzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng-Jie Jin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Medical College of Yangzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bao-Huan Zhou, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Medical College of Yangzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tian-Ming Gao, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Medical College of Yangzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guo-Qing Jiang, MD</last_name>
    <phone>86-514-87373372</phone>
    <email>jgqing2003@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dou-Sheng Bai, MD</last_name>
    <phone>86-514-87373375</phone>
    <email>bdsno1@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Medical College of Yangzhou University</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo-Qing Jiang, MS</last_name>
      <phone>86-514-87373372</phone>
      <email>jgqing2003@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dou-Sheng Bai, MD</last_name>
      <phone>86-514-87373375</phone>
      <email>bdsno1@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guo-Qing Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheng-Jie Jin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>December 26, 2020</last_update_submitted>
  <last_update_submitted_qc>December 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Guo-Qing Jiang</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Venous thrombosis</keyword>
  <keyword>Portal Hypertension</keyword>
  <keyword>Apixaban</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Splenectomy</keyword>
  <keyword>Laparoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

